{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:51Z","timestamp":1790484351014,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bone.2021.116137","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T11:51:01Z","timestamp":1627732261000},"page":"116137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase\u00ae)"],"prefix":"10.1016","volume":"153","author":[{"given":"Benjamin","family":"Batteux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hurtel-Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116137_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2021.116137_bb0015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pmrj.2008.12.005","article-title":"A review of osteoporosis: part I. impact, pathophysiology, diagnosis and unique role of the physiatrist","volume":"1","author":"Kasturi","year":"2009","journal-title":"PM&R"},{"key":"10.1016\/j.bone.2021.116137_bb0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","article-title":"Glucocorticoid-induced osteoporosis update","volume":"31","author":"Adami","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bone.2021.116137_bb0025","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.bone.2021.116137_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1742-7843.2008.00337.x","article-title":"The effect of aromatase inhibitors on bone metabolism","volume":"104","author":"Folkestad","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bone.2021.116137_bb0035","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer."},{"key":"10.1016\/j.bone.2021.116137_bb0040","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.surg.2011.09.013","article-title":"Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study","volume":"150","author":"Sugitani","year":"2011","journal-title":"Surgery."},{"key":"10.1016\/j.bone.2021.116137_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1463-1326.2008.00931.x","article-title":"Thiazolidinedione-induced skeletal fragility\u2014mechanisms and implications","volume":"11","author":"Grey","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bone.2021.116137_bb0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1756-185X.2009.01395.x","article-title":"Reduced bone density in patients on long-term warfarin","volume":"12","author":"Rezaieyazdi","year":"2009","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.116137_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2005.01585.x","article-title":"Fracture risk in patients treated with loop diuretics","volume":"259","author":"Rejnmark","year":"2006","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0065","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1089\/0889222041217482","article-title":"AZT enhances osteoclastogenesis and bone loss","volume":"20","author":"Pan","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses."},{"key":"10.1016\/j.bone.2021.116137_bb0070","doi-asserted-by":"crossref","first-page":"19247","DOI":"10.1074\/jbc.C200069200","article-title":"Select HIV protease inhibitors alter bone and fat metabolism ex vivo","volume":"277","author":"Jain","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2021.116137_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2796.2006.01667.x","article-title":"Fracture risk associated with the use of morphine and opiates","volume":"260","author":"Vestergaard","year":"2006","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00774-015-0732-9","article-title":"Bone mineral density and its determinants in men with opioid dependence","volume":"35","author":"Gotthardt","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2021.116137_bb0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ane.12118","article-title":"Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy","volume":"128","author":"Beerhorst","year":"2013","journal-title":"Acta Neurol. Scand"},{"key":"10.1016\/j.bone.2021.116137_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/JCP.0b013e3182075587","article-title":"Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women","volume":"31","author":"Bolton","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-200730020-00006","article-title":"Psychotropic medications and the risk of fracture: a meta-analysis","volume":"30","author":"Takkouche","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2021.116137_bb0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jbspin.2019.11.003","article-title":"Association between benzodiazepines use and risk of hip fracture in the elderly people: a meta-analysis of observational studies","volume":"87","author":"Poly","year":"2020","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.bone.2021.116137_bb0105","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bone.2012.05.018","article-title":"Antidepressant medications and osteoporosis","volume":"51","author":"Rizzoli","year":"2012","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00198-003-1577-y","article-title":"Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women\u2019s Health Study","volume":"15","author":"Lim","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0115","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-9378(94)70299-3","article-title":"A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry","volume":"170","author":"Barbour","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.bone.2021.116137_bb0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key concepts of clinical trials: a narrative review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad Med."},{"key":"10.1016\/j.bone.2021.116137_bb0125","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00228-008-0497-3","article-title":"Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?","volume":"64","author":"Sommet","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00228-019-02743-9","article-title":"Drug-induced osteoporosis\/osteomalacia: analysis in the French and Spanish pharmacovigilance databases","volume":"75","author":"Dardonville","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inform. J."},{"key":"10.1016\/j.bone.2021.116137_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug-Safety."},{"key":"10.1016\/j.bone.2021.116137_bb0155","author":"International Conference of Harmonization (ICH)"},{"key":"10.1016\/j.bone.2021.116137_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2021.116137_bb0165","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","article-title":"Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance","volume":"9","author":"Roux","year":"2005","journal-title":"IEEE Trans. Inf. Technol. Biomed."},{"key":"10.1016\/j.bone.2021.116137_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2021.116137_bb0175","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","article-title":"Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area","volume":"70","author":"Grundmark","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Association Fran\u00e7aise des Centres R\u00e9gionaux de Pharmacovigilance (CRPV), effect of competition bias in safety signal generation","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2021.116137_bb0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","article-title":"A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France","volume":"36","author":"Salvo","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2021.116137_bb0190","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-129-10-199811150-00003","article-title":"Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture","volume":"129","author":"Melhus","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0306-3623(91)90450-K","article-title":"Effects of retinoic acid on bone formation and resorption in cultured mouse calvaria","volume":"22","author":"Togari","year":"1991","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.bone.2021.116137_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/8756-3282(90)90072-7","article-title":"Retinoic acid and 1,25-dihydroxyvitamin D3 stimulate osteoclast formation by different mechanisms","volume":"11","author":"Scheven","year":"1990","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0205","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jn\/129.12.2246","article-title":"Vitamin A antagonizes the action of vitamin D in rats","volume":"129","author":"Rohde","year":"1999","journal-title":"J. Nutr."},{"key":"10.1016\/j.bone.2021.116137_bb0210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12020-020-02277-6","article-title":"Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice","volume":"69","author":"Mazziotti","year":"2020","journal-title":"Endocrine."},{"key":"10.1016\/j.bone.2021.116137_bb0215","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2021.116137_bb0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jsbmb.2009.08.004","article-title":"Dihydrotestosterone is a determinant of calcaneal bone mineral density in men","volume":"117","author":"Ilangovan","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bone.2021.116137_bb0225","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1210\/endo-114-6-2100","article-title":"Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin","volume":"114","author":"Saartok","year":"1984","journal-title":"Endocrinology."},{"key":"10.1016\/j.bone.2021.116137_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140598","article-title":"Risk of fractures and falls during and after 5-\u03b1 reductase inhibitor use: a nationwide cohort study","volume":"10","author":"Robinson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2021.116137_bb0235","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00198-010-1320-4","article-title":"Risk of fractures associated with treatment for benign prostate hyperplasia in men","volume":"22","author":"Vestergaard","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0240","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cen.12599","article-title":"A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia","volume":"82","author":"Lin","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bone.2021.116137_bb0245","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/sj.leu.2402078","article-title":"Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development","volume":"15","author":"Kaste","year":"2001","journal-title":"Leukemia."},{"key":"10.1016\/j.bone.2021.116137_bb0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00003086-197706000-00021","article-title":"Fractures in children treated with methotrexate for leukemia","author":"Stanisavljevic","year":"1977","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0255","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/1097-0142(197602)37:2+<1048::AID-CNCR2820370811>3.0.CO;2-V","article-title":"Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems","volume":"37","author":"Nesbit","year":"1976","journal-title":"Cancer."},{"key":"10.1016\/j.bone.2021.116137_bb0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0026-0495(65)80035-X","article-title":"Metabolic studies of the effects of methotrexate","volume":"14","author":"Nevinny","year":"1965","journal-title":"Metabolism."},{"key":"10.1016\/j.bone.2021.116137_bb0265","first-page":"1305","article-title":"Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study","volume":"31","author":"Munno","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.116137_bb0270","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-005-0657-9","article-title":"Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study","volume":"24","author":"Arai","year":"2006","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2021.116137_bb0275","first-page":"2395","article-title":"The effect of low dose methotrexate on bone density","volume":"28","author":"Cranney","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.116137_bb0280","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","article-title":"Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density","volume":"41","author":"Minaur","year":"2002","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.bone.2021.116137_bb0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s001980050189","article-title":"Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis","volume":"10","author":"Bianchi","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0290","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1590\/S0004-27302006000400023","article-title":"Transplantation osteoporosis","volume":"50","author":"Kulak","year":"2006","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.bone.2021.116137_bb0295","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jbmr.5650040314","article-title":"Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption","volume":"4","author":"Movsowitz","year":"1989","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0300","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.3390\/ijms20236085","article-title":"Azathioprine has a deleterious effect on the bone health of mice with DSS-induced inflammatory bowel disease","volume":"20","author":"Morgan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2021.116137_bb0305","first-page":"309","article-title":"Alendronate prevents development of the skeletal changes induced by azathioprine in rats","volume":"70","author":"Cegie\u0142a","year":"2013","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.bone.2021.116137_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00223-006-0060-0","article-title":"Methotrexate, azathioprine, cyclosporine, and risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116137_bb0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S8756-3282(97)00147-6","article-title":"The in vivo anabolic actions of prostaglandins in bone","volume":"21","author":"Jee","year":"1997","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0320","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/15513819609168686","article-title":"Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms","volume":"16","author":"Faye-Petersen","year":"1996","journal-title":"Pediatr. Pathol. Lab. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.116137_bb0325","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF01621888","article-title":"Prostaglandins: mechanisms of action and regulation of production in bone","volume":"3","author":"Raisz","year":"1993","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026876","article-title":"Aspirin and fracture risk: a systematic review and exploratory meta-analysis of observational studies","volume":"10","author":"Barker","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.bone.2021.116137_bb0335","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00198-006-0142-x","article-title":"The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study","volume":"17","author":"Richards","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0340","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1359\/jbmr.2003.18.10.1795","article-title":"Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity","volume":"18","author":"Carbone","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0345","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jcb.25380","article-title":"C-Mpl is expressed on osteoblasts and osteoclasts and is important in regulating skeletal homeostasis","volume":"117","author":"Meijome","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2021.116137_bb0350","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/jcp.24943","article-title":"A novel role for thrombopoietin in regulating osteoclast development in humans and mice","volume":"230","author":"Bethel","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bone.2021.116137_bb0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S8756-3282(03)00215-1","article-title":"Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures","volume":"33","author":"Schroeder","year":"2003","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0360","first-page":"E797","article-title":"Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra- and intracellular pools in osteoblastic cells","volume":"257","author":"Takuwa","year":"1989","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.bone.2021.116137_bb0365","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s002239900245","article-title":"Endothelin-1 is a potent regulator of human bone cell metabolism in vitro","volume":"60","author":"Kasperk","year":"1997","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116137_bb0370","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1080\/09513590903015429","article-title":"Postmenopausal women with osteoporosis may be associated with high endothelin-1","volume":"25","author":"Gulhan","year":"2009","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.bone.2021.116137_bb0375","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1152\/ajpendo.00026.2003","article-title":"In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria","volume":"285","author":"Kondo","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2021.116137_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50336-4","article-title":"Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson\u2019s disease model mice","volume":"9","author":"Handa","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2021.116137_bb0385","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.bone.2021.116137_bb0390","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa032546","article-title":"Homocysteine levels and the risk of osteoporotic fracture","volume":"350","author":"Meurs","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0395","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00223-007-9099-9","article-title":"Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture","volume":"82","author":"Vestergaard","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116137_bb0400","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","article-title":"Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum","volume":"135","author":"Yadav","year":"2008","journal-title":"Cell."},{"key":"10.1016\/j.bone.2021.116137_bb0405","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1590\/1414-431X20143565","article-title":"Serotonin regulates osteoblast proliferation and function in vitro","volume":"47","author":"Dai","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0410","doi-asserted-by":"crossref","unstructured":"B. Lavoie, J.B. Lian, G.M. Mawe, Regulation of bone metabolism by serotonin, Adv. Exp. Med. Biol. 1033 (2017) 35\u201346. doi:https:\/\/doi.org\/10.1007\/978-3-319-66653-2_3.","DOI":"10.1007\/978-3-319-66653-2_3"},{"key":"10.1016\/j.bone.2021.116137_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(99)00241-0","article-title":"Toward a unifying theory of bone remodeling","volume":"26","author":"Martin","year":"2000","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2012.00089","article-title":"Glutamate signaling in healthy and diseased bone","volume":"3","author":"Cowan","year":"2012","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bone.2021.116137_bb0425","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00198-005-1928-y","article-title":"Down-regulation of N-methyl d-aspartate receptor in rat-modeled disuse osteopenia","volume":"16","author":"Ho","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0430","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bone.2016.06.013","article-title":"The roles of vascular endothelial growth factor in bone repair and regeneration","volume":"91","author":"Hu","year":"2016","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0435","article-title":"Mechanism of dexmedetomidine regulating osteogenesis-angiogenesis coupling through the miR-361-5p\/VEGFA axis in postmenopausal osteoporosis","author":"Wang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bone.2021.116137_bb0440","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1359\/jbmr.090724","article-title":"Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians","volume":"25","author":"Chen","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0445","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bone.2011.04.020","article-title":"Osteoblast\/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species","volume":"49","author":"Zhou","year":"2011","journal-title":"Bone."},{"key":"10.1016\/j.bone.2021.116137_bb0450","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bbrc.2005.01.019","article-title":"Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice","volume":"328","author":"Zhang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2021.116137_bb0455","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116137_bb0460","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.14486","article-title":"The NO-cGMP-PKG pathway in skeletal remodeling","volume":"1487","author":"Kim","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bone.2021.116137_bb0465","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.20206","article-title":"The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1","volume":"50","author":"Urushibara","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.116137_bb0470","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00296-008-0682-9","article-title":"Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis","volume":"29","author":"Pfeil","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0475","first-page":"213","article-title":"TNF-\u03b1 and IL-6: the link between immune and bone system","volume":"21","author":"Wang","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bone.2021.116137_bb0480","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/jcm10061241","article-title":"Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview","volume":"10","author":"Tanaka","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bone.2021.116137_bb0485","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2021.116137_bb0490","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","article-title":"IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522)","volume":"42","author":"Karsdal","year":"2012","journal-title":"Semin. Arthr. Rheum."},{"key":"10.1016\/j.bone.2021.116137_bb0495","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00223-018-0401-9","article-title":"Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton","volume":"102","author":"Dubrovsky","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2021.116137_bb0500","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2007.080713","article-title":"CTLA-4 directly inhibits osteoclast formation","volume":"67","author":"Axmann","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.116137_bb0505","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/annrheumdis-2015-eular.2214","article-title":"FRI0062 influence of biologic agents on bone mineral density and bone mineral markers in patients with rheumatoid arthritis: data from the airtight study","volume":"74","author":"Tada","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2021.116137_bb0510","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-010-1560-9","article-title":"Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study","volume":"31","author":"Hein","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201527","article-title":"Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study","volume":"13","author":"Wheater","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2021.116137_bb0520","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jcp.26028","article-title":"Hydroxychloroquine affects bone resorption both in vitro and in vivo","volume":"233","author":"Both","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bone.2021.116137_bb0525","first-page":"102","article-title":"Factors associated with low bone mineral density in female patients with systemic lupus erythematosus","volume":"28","author":"Lakshminarayanan","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2021.116137_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10393","article-title":"The association of methotrexate, sulfasalazine, and hydroxychloroquine use with fracture in postmenopausal women with rheumatoid arthritis: findings from the Women\u2019s Health Initiative","volume":"4","author":"Carbone","year":"2020","journal-title":"JBMR Plus."},{"key":"10.1016\/j.bone.2021.116137_bb0535","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/416744a","article-title":"RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta","volume":"416","author":"Takayanagi","year":"2002","journal-title":"Nature."},{"key":"10.1016\/j.bone.2021.116137_bb0540","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1352458506070605","article-title":"Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients","volume":"12","author":"Weinstock-Guttman","year":"2006","journal-title":"Mult. Scler."},{"key":"10.1016\/j.bone.2021.116137_bb0545","first-page":"901","article-title":"Bone mineral density in patients with multiple sclerosis: the effects of interferon","volume":"36","author":"Castrill\u00f3n","year":"2003","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.bone.2021.116137_bb0550","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy."},{"key":"10.1016\/j.bone.2021.116137_bb0555","first-page":"106","article-title":"Nucala (mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma","volume":"9","author":"Fala","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.bone.2021.116137_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030712","article-title":"Does allergy break bones? Osteoporosis and its connection to allergy","volume":"21","author":"Sirufo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2021.116137_bb0565","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2014.104463","article-title":"Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels","volume":"99","author":"Rossi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2021.116137_bb0570","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00198-008-0701-4","article-title":"Association between iron overload and osteoporosis in patients with hereditary hemochromatosis","volume":"20","author":"Valenti","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116137_bb0575","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00277-016-2633-y","article-title":"Longitudinal changes of endocrine and bone disease in adults with \u03b2-thalassemia major receiving different iron chelators over 5\u00a0years","volume":"95","author":"Poggi","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bone.2021.116137_bb0580","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1093\/ndt\/gfr214","article-title":"Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis\u2014implications for post-transplantation bone disease","volume":"26","author":"Westenfeld","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bone.2021.116137_bb0585","first-page":"1515","article-title":"Decreased retinol transport proteins in Thai post-menopausal women with osteoporosis","volume":"42","author":"Chupeerach","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"10.1016\/j.bone.2021.116137_bb0590","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"Brink","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.bone.2021.116137_bb0595","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","article-title":"Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases","volume":"134","author":"Khouri","year":"2021","journal-title":"J. Clin. Epidemiol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221003021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221003021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:45:55Z","timestamp":1762659955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221003021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":118,"alternative-id":["S8756328221003021"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116137","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase\u00ae)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116137"}}